ABSTRACT
AIMS: Ursodeoxycholic acid (UDCA) is a hydrophilic dihydroxy bile acid used for cholestatic liver disease and exhibits antioxidant, antitumor, and anti-inflammatory effects. However, its potential effects on atopic dermatitis (AD) have not been elucidated. This study aimed to evaluate the efficacy of UDCA in inhibiting the inflammatory response and alleviating lesions in AD-like mice. MAIN METHODS: To investigate the efficacy of UDCA in AD-like inflammatory responses, tumor necrosis factor-alpha (TNF-α)- and interferon-gamma (IFN-γ)-stimulated HaCaT cells and anti-dinitrophenyl immunoglobulin E (DNP-IgE)- and human serum albumin (HSA)-stimulated RBL-2H3 cells were used to investigate the levels of inflammatory factors and their mechanisms. AD-like lesions were induced by applying DNCB/DFE to mice. The effect of UDCA administration in AD-like mice was analyzed by assessing organ weight, serum IgE and inflammatory cytokine levels, and histopathological changes using immunohistochemical and immunofluorescent staining. KEY FINDINGS: In HaCaT cells, UDCA significantly diminished TARC, MDC, MCP-1, and IL-6 expression by inhibiting the phosphorylation of nuclear NF-κB and cytoplasmic IκB, and also increased the levels of skin barrier protein. In RBL-2H3 cells, UDCA reduced ß-hexosaminidase and IL-4 levels. In AD-like mice, UDCA suppressed organ hypertrophy, ear edema, SCORAD index, DFE-specific IgE levels, inflammatory cytokine levels, skin hypertrophy, mast cell invasion, skin barrier loss, and thymic stromal lymphopoietin-positive areas. SIGNIFICANCE: UDCA suppressed the expression of pro-inflammatory cytokines by keratinocytes and mast cells. It also alleviated atopy by suppressing symptoms without organ toxicity in AD-like mice. UDCA may be an effective and safe treatment for AD.
Subject(s)
Dermatitis, Atopic , Humans , Animals , Mice , Rats , Dermatitis, Atopic/chemically induced , Skin , Dinitrochlorobenzene , Ursodeoxycholic Acid/pharmacology , Ursodeoxycholic Acid/metabolism , Cytokines/metabolism , NF-kappa B/metabolism , Immunoglobulin E , Hypertrophy/metabolism , Mice, Inbred BALB CABSTRACT
Osteoporosis is a debilitating condition characterized by reduced bone mass and density, leading to compromised structural integrity of the bones. While conventional treatments, such as bisphosphonates and selective estrogen receptor modulators (SERMs), have been employed to mitigate bone loss, their effectiveness is often compromised by a spectrum of adverse side effects, ranging from gastrointestinal discomfort and musculoskeletal pain to more severe concerns like atypical fractures and hormonal imbalances. Daucosterol (DC), a natural compound derived from various plant sources, has recently garnered considerable attention in the field of pharmacology. In this study, we investigated the anti-osteoporosis potential of DC by characterizing its role in osteoclasts, osteoblasts, and lipopolysaccharide (LPS)-induced osteoporosis. The inhibitory effect of DC on osteoclast differentiation was determined by tartrate-resistant acid phosphatase (TRAP) staining, F-actin ring formation by fluorescent staining, and bone resorption by pit formation assay. In addition, the calcification nodule deposition effect of osteoblasts was determined by Alizarin red S staining. The effective mechanisms of both cells were verified by Western blot and reverse transcription polymerase chain reaction (RT-PCR). To confirm the effect of DC in vivo, DC was administered to a model of osteoporosis by intraperitoneal administration of LPS. The anti-osteoporosis effect was then characterized by micro-CT and serum analysis. The results showed that DC effectively inhibited osteoclast differentiation at an early stage, promoted osteoblast activity, and inhibited LPS-induced bone density loss. The results of this study suggest that DC can treat osteoporosis through osteoclast and osteoblast regulation, and therefore may be considered as a new therapeutic alternative for osteoporosis patients in the future.
Subject(s)
Bone Resorption , Osteoporosis , Humans , Osteoclasts , Lipopolysaccharides/pharmacology , Cell Differentiation , Osteoblasts , Bone Resorption/drug therapy , Osteoporosis/drug therapy , RANK Ligand/pharmacology , OsteogenesisABSTRACT
[This corrects the article DOI: 10.1039/D2RA05027G.].
ABSTRACT
In order to improve the electrocatalytic activity and stability of an iridium (Ir) nanoparticle catalyst toward the oxygen evolution reaction (OER) in acidic electrolyte, carbon nanotube and titanium dioxide nanocomposites (CNT@TiO2) are presented as a high-performance support. TiO2 was synthesized on CNTs by using a novel layer-by-layer solution coating method that mimics atomic layer deposition (ALD) but is cost-effective and scalable. In the nanocomposites, CNTs serve as the electron pathways and the surface TiO2 layers protect CNTs from corrosion under the harsh OER conditions. Thus, CNT@TiO2 demonstrates excellent corrosion resistance as well as a high electrical conductivity (1.6 ± 0.2 S cm-1) comparable to that of Vulcan carbon (1.4 S cm-1). The interaction between Ir and TiO2 promotes the formation of Ir(iii) species, thereby enhancing the OER activity and stability of the Ir nanoparticle catalyst. Compared to commercial carbon-supported Ir (Ir/C) and Ir black catalysts, CNT@TiO2-supported Ir exhibits superior OER activity and stability.
ABSTRACT
Atopic dermatitis (AD) is a chronic inflammatory allergic skin disease, characterized by pruritic and eczematous skin lesions. Lycopus lucidus Turcz (LLT) is a perennial herb that has been reported to have various biological properties, including effects on blood circulation, as well as antiinflammatory, antioxidant, antivascular inflammation and woundhealing effects. However, whether LLT improves dermatitis and the underlying mechanisms has yet to be determined. The aim of the present study was to determine whether LLT can improve 2,4dinitrochlorobenzene (DNCB)induced dermatitis and to verify the inhibitory effect of LLT on the expression of chemokines and proinflammatory cytokines in the HaCaT immortalized keratinocyte cell line. In addition, the antiinflammatory function of LLT in RAW264.7 mouse macrophages was investigated. In the DNCBinduced AD mouse model, LLT inhibited infiltration by mast cells, eosinophils and CD8+ cells in the dorsal skin tissue of AD mice, and suppressed the expression of IgE and IL6 in serum. In addition, LLT inhibited the phosphorylation of ERK and JNK, as well as NFκB in skin tissue. In the HaCaT cell model induced by TNFα/IFNγ, LLT inhibited the expression of thymus and activationregulated chemokine, granulocytemacrophage colonystimulating factor, monocyte chemoattractant protein1, TNFα and IL1ß, whilst inhibiting the phosphorylation of NFκB. In addition, in the lipopolysaccharideinduced RAW 264.7 cell inflammation model, LLT inhibited the expression of TNFα and IFNγ, the nuclear translocation of NFκB and the phosphorylation of ERK and JNK. These results suggested that LLT may be a promising candidate for the treatment of inflammatory dermatitis.
Subject(s)
Chemokines/metabolism , Cytokines/metabolism , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/metabolism , Lycopus/chemistry , Macrophages/metabolism , Plant Extracts/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , CD8-Positive T-Lymphocytes/metabolism , Dinitrochlorobenzene , Disease Models, Animal , Eosinophils/metabolism , HaCaT Cells , Humans , MAP Kinase Kinase 4/metabolism , MAP Kinase Signaling System/drug effects , Macrophages/drug effects , Male , Mast Cells/metabolism , Medicine, Chinese Traditional , Mice , Mice, Inbred BALB C , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Skin/pathology , Wound Healing/drug effectsABSTRACT
Postmenopausal osteoporosis is caused by an imbalance between osteoclasts and osteoblasts and causes severe bone loss. Osteoporotic medicines are classified into bone resorption inhibitors and bone formation promoters according to the mechanism of action. Long-term use of bisphosphonate and selective estrogen receptor modulators (SERMs) can cause severe side effects in postmenopausal osteoporosis patients. Therefore, it is important to find alternative natural products that reduce osteoclast activity and increase osteoblast formation. Sparganii Rhizoma (SR) is the dried tuberous rhizome of Sparganium stoloniferum Buchanan-Hamilton and is called "samreung" in Korea. However, to date, the effect of SR on osteoclast differentiation and the ovariectomized (OVX)-induced bone loss model has not been reported. In vitro, tartrate-resistant acid phosphatase (TRAP) staining, western blots, RT-PCR and other methods were used to examine the effect of SR on osteoclast differentiation and osteoblasts. In vivo, we confirmed the effect of SR in a model of OVX-induced postmenopausal osteoporosis. SR inhibited osteoclast differentiation and decreased the expression of TNF receptor-associated factor 6 (TRAF6), nuclear factor of activated T cells 1 (NFATc1) and c-Fos pathway. In addition, SR stimulates osteoblast differentiation and increased protein expression of the bone morphogenetic protein 2 (BMP-2)/SMAD signaling pathway. Moreover, SR protected against bone loss in OVX-induced rats. Our results appear to advance our knowledge of SR and successfully demonstrate its potential role as a osteoclastogenesis-inhibiting and osteogenesis-promoting herbal medicine for the treatment of postmenopausal osteoporosis.